{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:16:08Z","timestamp":1787836568365,"version":"build-2784847793"},"reference-count":38,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Glasgow NHS GGC Trusted Research Environment"},{"name":"oGRE Challenge"},{"name":"Glasgow Living Laboratory for Precision Medicine"},{"name":"UKRI Strength in Places Fund","award":["SIPF00007\/1"],"award-info":[{"award-number":["SIPF00007\/1"]}]},{"name":"UKRI Strength in Places Fund","award":["321198"],"award-info":[{"award-number":["321198"]}]},{"DOI":"10.13039\/100010526","name":"NHS Greater Glasgow and Clyde","doi-asserted-by":"publisher","award":["GSH22ME007"],"award-info":[{"award-number":["GSH22ME007"]}],"id":[{"id":"10.13039\/100010526","id-type":"DOI","asserted-by":"publisher"}]},{"name":"British Heart Foundation Centre for Research Excellence","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00022\/2"],"award-info":[{"award-number":["MC_UU_00022\/2"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scottish Government Chief Scientist Office","award":["SPHSU17"],"award-info":[{"award-number":["SPHSU17"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Hypogonadism is a common endocrine disorder in aging men, associated with adverse cardiometabolic outcomes. Concerns about the cardiovascular (CV) safety of testosterone, an important therapy option for the condition, may be disproportionately influencing treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This work aimed to investigate the association between long-term testosterone therapy and major adverse CV events (MACE) in men aged 51 years and older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used linked health data from the National Health Service Greater Glasgow and Clyde population, accessed via the West of Scotland Safe Haven. Men aged 51 years and older as of January 1, 2012, were included. Testosterone exposure was defined as having at least a 2-year interval between the first and last prescription during a 5-year exposure window (2012-2016). Individuals were followed from January 1, 2017, to December 31, 2022. The primary outcome was time to first MACE, defined as a composite of acute myocardial infarction, unstable angina, stroke, heart failure, or CV death. Cox proportional hazards models were used to estimate associations, adjusting for age, ethnicity, socioeconomic deprivation, and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 440 testosterone-exposed and 136 051 unexposed men. Testosterone exposure was associated with a 54% increased risk of MACE in the unadjusted analysis (hazard ratio [HR]: 1.54; 95% CI, 1.18-2.00), and a 55% increased risk after adjustment (HR: 1.55; 95% CI, 1.19-2.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort, long-term testosterone therapy was associated with increased CV risk. While recent trials inform short- to medium-term CV safety, this study underscores the need for more longer-term data to fully ascertain the effect of testosterone therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf156","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T11:48:54Z","timestamp":1759578534000},"source":"Crossref","is-referenced-by-count":1,"title":["Association Between Long-Term Testosterone Exposure and Major Adverse Cardiovascular Events in Aging Men"],"prefix":"10.1210","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-9977","authenticated-orcid":false,"given":"Paul J","family":"Connelly","sequence":"first","affiliation":[{"name":"Department of Endocrinology & Diabetes, Queen Elizabeth University Hospital , Glasgow G51 4TF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5711-7240","authenticated-orcid":false,"given":"Samuel","family":"Owusu Achiaw","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1658-3883","authenticated-orcid":false,"given":"Jocelyn M","family":"Friday","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-9025","authenticated-orcid":false,"given":"Frederick K","family":"Ho","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Geue","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-5808","authenticated-orcid":false,"given":"Sandosh","family":"Padmanabhan","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill P","family":"Pell","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5381-7098","authenticated-orcid":false,"given":"Daniel F","family":"Mackay","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Dundas","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran Q B","family":"Tran","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Brown","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4604-3319","authenticated-orcid":false,"given":"Claire E","family":"Hastie","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-4502","authenticated-orcid":false,"given":"Michael","family":"Fleming","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Stevenson","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clea","family":"du Toit","sequence":"additional","affiliation":[{"name":"The Living Laboratory, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Lewsey","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-2612","authenticated-orcid":false,"given":"Christian","family":"Delles","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, University of Glasgow , Glasgow G12 8TB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"2","key":"2025102802162677400_bvaf156-B1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/cen.14633","article-title":"Society for endocrinology guidelines for testosterone replacement therapy in male hypogonadism","volume":"96","author":"Jayasena","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2025102802162677400_bvaf156-B2","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1210\/jc.2003-031719","article-title":"Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study","volume":"89","author":"Araujo","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025102802162677400_bvaf156-B3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2213-8587(24)00199-2","article-title":"Male hypogonadism: pathogenesis, diagnosis, and management","volume":"12","author":"De Silva","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2025102802162677400_bvaf156-B4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.7326\/M23-2781","article-title":"Associations of testosterone and related hormones with all-cause and cardiovascular mortality and incident cardiovascular disease in men\u202f: individual participant data meta-analyses","volume":"177","author":"Yeap","year":"2024","journal-title":"Ann Intern Med"},{"issue":"7","key":"2025102802162677400_bvaf156-B5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2025102802162677400_bvaf156-B6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamainternmed.2016.9540","article-title":"Association of testosterone levels with anemia in older men: a controlled clinical trial","volume":"177","author":"Roy","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2025102802162677400_bvaf156-B7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2025102802162677400_bvaf156-B8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1210\/jc.2013-3570","article-title":"Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011","volume":"99","author":"Layton","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025102802162677400_bvaf156-B9","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2666-7568(22)00096-4","article-title":"Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis","volume":"3","author":"Hudson","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"2025102802162677400_bvaf156-B10","doi-asserted-by":"crossref","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"issue":"17","key":"2025102802162677400_bvaf156-B11","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"2025102802162677400_bvaf156-B12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2025102802162677400_bvaf156-B13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.13589","article-title":"The state of testosterone therapy since the FDA's 2015 labelling changes: indications and cardiovascular risk","volume":"89","author":"Miner","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025102802162677400_bvaf156-B14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025102802162677400_bvaf156-B15","author":"OpenPrescribing"},{"issue":"3","key":"2025102802162677400_bvaf156-B16","doi-asserted-by":"crossref","first-page":"714F","DOI":"10.1093\/ije\/dyw060","article-title":"Data resource profile: the Scottish national prescribing information system (PIS)","volume":"45","author":"Alvarez-Madrazo","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"4","key":"2025102802162677400_bvaf156-B17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/oxfordjournals.pubmed.a024546","article-title":"The public health uses of the Scottish community health Index (CHI)","volume":"18","author":"Womersley","year":"1996","journal-title":"J Public Health Med"},{"key":"2025102802162677400_bvaf156-B18","unstructured":"Owusu Achiaw S . Supplementary material_association between long-term testosterone exposure and major adverse cardiovascular events in Ageing Men.docx. Figshare. doi:10.6084\/M9.FIGSHARE.30129046.V1. Published online September 15, 2025."},{"issue":"1","key":"2025102802162677400_bvaf156-B19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"10120","key":"2025102802162677400_bvaf156-B20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"issue":"9596","key":"2025102802162677400_bvaf156-B21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"2025102802162677400_bvaf156-B22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.amjmed.2019.03.022","article-title":"Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study","volume":"132","author":"Loo","year":"2019","journal-title":"Am J Med"},{"issue":"9","key":"2025102802162677400_bvaf156-B23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/1060028014539918","article-title":"Risk of myocardial infarction in older men receiving testosterone therapy","volume":"48","author":"Baillargeon","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2025102802162677400_bvaf156-B24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamainternmed.2016.9546","article-title":"Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency","volume":"177","author":"Cheetham","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2025102802162677400_bvaf156-B25","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/jc.2011-2591","article-title":"Testosterone treatment and mortality in men with low testosterone levels","volume":"97","author":"Shores","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025102802162677400_bvaf156-B26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"40","key":"2025102802162677400_bvaf156-B27","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","article-title":"Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men","volume":"36","author":"Sharma","year":"2015","journal-title":"Eur Heart J"},{"issue":"6","key":"2025102802162677400_bvaf156-B28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-8587(16)00112-1","article-title":"Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study","volume":"4","author":"Wallis","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2025102802162677400_bvaf156-B29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.amjcard.2015.11.063","article-title":"Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system","volume":"117","author":"Anderson","year":"2016","journal-title":"Am J Cardiol"},{"issue":"8","key":"2025102802162677400_bvaf156-B30","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.amjcard.2019.07.019","article-title":"Relation of testosterone normalization to mortality and myocardial infarction in men with previous myocardial infarction","volume":"124","author":"Oni","year":"2019","journal-title":"Am J Cardiol"},{"issue":"17","key":"2025102802162677400_bvaf156-B31","doi-asserted-by":"crossref","first-page":"e020562","DOI":"10.1161\/JAHA.120.020562","article-title":"Association between testosterone treatment and risk of incident cardiovascular events among US male veterans with low testosterone levels and multiple medical comorbidities","volume":"10","author":"Shores","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"2025102802162677400_bvaf156-B32","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamainternmed.2015.1573","article-title":"Comparative safety of testosterone dosage forms","volume":"175","author":"Layton","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2025102802162677400_bvaf156-B33","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1742-1241.2006.00992.x","article-title":"Prevalence of hypogonadism in males aged at least 45 years: the HIM study","volume":"60","author":"Mulligan","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"4","key":"2025102802162677400_bvaf156-B34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40471-018-0164-x","article-title":"Measurement error and misclassification in electronic medical records: methods to mitigate bias","volume":"5","author":"Young","year":"2018","journal-title":"Curr Epidemiol Rep"},{"issue":"5","key":"2025102802162677400_bvaf156-B35","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1177\/1557988316648704","article-title":"The availability and acquisition of illicit anabolic androgenic steroids and testosterone preparations on the internet","volume":"12","author":"McBride","year":"2016","journal-title":"Am J Mens Health"},{"key":"2025102802162677400_bvaf156-B36","doi-asserted-by":"crossref","first-page":"j4587","DOI":"10.1136\/bmj.j4587","article-title":"Handling time varying confounding in observational research","volume":"359","author":"Mansournia","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"2025102802162677400_bvaf156-B37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/JU.0000000000003786","article-title":"Rises in hematocrit are associated with an increased risk of major adverse cardiovascular events in men starting testosterone therapy: a retrospective cohort claims database analysis","volume":"211","author":"Kohn","year":"2024","journal-title":"J Urol"},{"issue":"2","key":"2025102802162677400_bvaf156-B38","first-page":"83","article-title":"Male obesity-related secondary hypogonadism\u2014pathophysiology, clinical implications and management","volume":"15","author":"Fernandez","year":"2019","journal-title":"Eur Endocrinol"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf156\/64540783\/bvaf156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/11\/bvaf156\/64540783\/bvaf156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/11\/bvaf156\/64540783\/bvaf156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T06:16:41Z","timestamp":1761632201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf156\/8277111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10,8]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf156","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,7]]},"article-number":"bvaf156"}}